Published: Wednesday, March 20, 2024 · 10:23 AM | Updated: Wednesday, March 20, 2024 · 10:23 AM
📊 564 views
Jan 31, 2024 / 11:30AM GMT
Operator
Ladies and gentlmen, good day and welcome to Ajanta Pharma Q3 FY24 earnings conference call. (Operator Instructions) Please note that this conference is being recorded.
I now hand the conference over to Mr. Yogesh Agrawal, Managing Director of Ajanta Pharma Limited. Thank you and over to you, sir.
Yogesh Agrawal – Ajanta Pharma Ltd – Managing Director, Executive Director
Thank you. Good evening, everyone, and welcome to this earnings call. With me, I have Mr. Rajesh Agrawal, our Joint Managing Director; Mr. Arvind Agrawal, our CFO; and Mr. Rajeev Agrawal, our EVP, Finance and Investor Relations.
I hope that the results are already there with you. We will take you through the business-wise performance for the Q3 and nine months of the current year, along with the comparison of previous year same period.
I am pleased to inform you that the Board of Directors have approved the second interim dividend for the current year. The share of INR2 face value will receive a dividend of INR26 amounting to the dividend amount of INR327 crore. In
MORE IN INSIDE INVESTMENT NEWS
Nike stock: A Portfolio Warning After Disappointing Quarter
Published: Tuesday, June 30, 2026 · 11:47 PM
AeroVironment: Alpha Generation in the Drone Defense Market
Published: Monday, June 29, 2026 · 10:17 PM
